Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
6,151 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06125041 | Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC | recruiting | Phase 2 | 51 | Qianfoshan HospitalOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06125080 | The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) :Single-arm, Prospective, Open Clinical Study(UTILIZABLE) | recruiting | Phase 2 | 78 | Huihua XiongOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06125652 | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121557 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121570 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06122493 | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05444478 | Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma | recruiting | N/A | 274 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05494060 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma(EXPLORING) | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05866692 | A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 156 | TYK Medicines, IncINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06118307 | Shanghai Ovarian Cancer and Family Care Project | recruiting | — | 3,546 | Shanghai First Maternity and Infant HospitalOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06118762 | Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer | recruiting | Phase 4 | 30 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06120387 | Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer | recruiting | — | 90 | Xuesong LiOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05895825 | A Study of EOC237 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 48 | Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., LtdINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06114225 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial(PROMIS) | recruiting | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06074692 | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)(PRIMA) | recruiting | Phase 2 | 86 | Ruijin HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06102395 | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | recruiting | Phase 3 | 272 | Beijing Tongren HospitalOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06066905 | A Study of Chidamide With AZA in MRD Positive AML After Transplant | recruiting | N/A | 60 | Guangdong Provincial People's HospitalOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06104085 | 99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06104215 | BGT007H Cells for the Treatment of Refractory Digestive System Tumors | recruiting | Early Phase 1 | 14 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06104241 | BGT007 Cells for the Treatment of Refractory Digestive System Tumors | recruiting | Early Phase 1 | 14 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05916261 | Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 54 | Ruijin HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05985109 | KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 98 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06099821 | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | recruiting | Phase 2 | 39 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102759 | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102772 | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102785 | Fruquintinib Combined With TAS102 for Advanced Gastric Cancer | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102837 | Tumor Vaccines for Solid Tumors | recruiting | — | 340 | Huashan HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102928 | A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation | recruiting | N/A | 30 | Kunming Medical UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05997719 | Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC | recruiting | — | 150 | Sun Yat-sen UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06092086 | Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC | recruiting | Phase 2 | 126 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05624099 | Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. | recruiting | Phase 2 | 75 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 19, 2023 | clinicaltrials |
| NCT05260671 | Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN | recruiting | Phase 2 | 48 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06087068 | Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma | recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06084962 | A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | recruiting | Phase 1 | 40 | He HuangOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06082180 | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer | recruiting | Phase 3 | 1,199 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06082648 | Study of Brain-Gut Function Reconstruction After Intersphincteric Resection for Ultra-Low Rectal Tumors | recruiting | N/A | 57 | Huashan HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06082934 | Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 30 | Xijing HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06080776 | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | recruiting | Phase 3 | 242 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05777824 | Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy(HN) | recruiting | Phase 2 | 84 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05996458 | A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors | recruiting | — | 84,000 | Xijing HospitalOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT03964753 | Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma(NTNC) | recruiting | Phase 2 | 202 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05241028 | Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05749887 | The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer. | recruiting | N/A | 188 | Chongqing University Cancer HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05777278 | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06072989 | Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors | recruiting | Phase 1 | 24 | Shanghai East HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials